Duloxetine Delayed-Release Capsules USP recall
FDA recall D-0522-2026 · initiated Apr 21, 2026
Breckenridge Pharmaceutical, Inc. recalled Duloxetine Delayed-Release Capsules USP in Apr 2026 — an FDA Class II recall (D-0522-2026) because CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit.
May cause temporary or medically reversible harm; low probability of serious harm.
Why it was recalled
CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit
An impurity above the accepted limit
A by-product of manufacturing or storage exceeded the limit the FDA accepts. Nitrosamines are the common example: the concern is long-term exposure, not immediate danger from one dose.
This is a manufacturing or quality failure, not a finding that the medicine is unsafe to take — across every recall we hold, none was issued for that reason. It does not mean the batch was harmless.
Is your product affected? Check the lot number
A recall covers only specific lots. Find the lot number and expiration date on your package and compare them to the affected codes below — if yours is not listed, it was not part of this recall.
Quantity recalled: 165,761 90-count bottles
Details
- Product
- Duloxetine Delayed-Release Capsules USP, 60mg, Rx Only, 90-count bottle, Mfr. by Towa Pharmaceutical Eurpoe S.L., Martorelles, (Barcelona), Spain, Dist. by. Breckenridge Pharmaceutical, Inc., Berkely Heights, NJ 07922, NDC 51991-748-90.
- Recalling company
- Breckenridge
- Classification
- Class II
- Status
- Ongoing
- Type
- Voluntary: Firm initiated
- Distribution
- Nationwide in the USA
- Initiated
- Apr 21, 2026
- FDA report date
- May 13, 2026
Frequently asked
- Was Duloxetine Delayed-Release Capsules USP recalled?
- Breckenridge Pharmaceutical, Inc. recalled Duloxetine Delayed-Release Capsules USP in Apr 2026 — an FDA Class II recall (D-0522-2026) because CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit. May cause temporary or medically reversible harm; low probability of serious harm.
- Why was Duloxetine Delayed-Release Capsules USP recalled?
- Per the FDA enforcement record, the reason for recall D-0522-2026 was: CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit
- Is a recalled Duloxetine Delayed-Release Capsules USP dangerous to take?
- An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. May cause temporary or medically reversible harm; low probability of serious harm. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
- Which lots of Duloxetine Delayed-Release Capsules USP are affected?
- Distributed: Nationwide in the USA. The recall covers these lots — Lot: 241069C, Exp 05/31/2027. Check the lot number and expiration date on your package against this list; if yours is not listed, it was not part of recall D-0522-2026.